Out of the 78 glioma specimens, 50 (64.1%), 40 (51.3%) and 45 (57.7%) exhibited high expression levels with MAGE-A1, -A3 and -A11 antibodies, respectively (Table I). Here, MAGEA1 is linked to central nervous system cancer.